Language selection

Search

Details for: XGEVA

Company: AMGEN CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02368153XGEVADENOSUMAB120 MG / 1.7 MLSOLUTIONSUBCUTANEOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness
Summary Safety Review - PROLIA (denosumab) - Cardiovascular events
Summary Safety Review - PROLIA (denosumab) - Risk of Malignancy (Cancer)

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: